Dopamine D1-D2 receptor Heteromer-mediated calcium release is desensitized by D1 receptor occupancy with or without signal activation: dual functional regulation by G protein-coupled receptor kinase 2.
We identified that activation of the G(q)-linked dopamine D1-D2 receptor hetero-oligomer generates a PLC-dependent intracellular calcium signal. Confocal FRET between endogenous dopamine D1 and D2 receptors in striatal neurons confirmed a physical interaction between them. Pretreatment with SKF 83959, which selectively activates the D1-D2 receptor heteromer, or SKF 83822, which only activates the D1 receptor homo-oligomer, led to rapid desensitization of the D1-D2 receptor heteromer-mediated calcium signal in both heterologous cells and striatal neurons. This desensitization response was mediated through selective occupancy of the D1 receptor binding pocket. Although SKF 83822 was unable to activate the D1-D2 receptor heteromer, it still permitted desensitization of the calcium signal. This suggested that occupancy of the D1 receptor binding pocket by SKF 83822 resulted in conformational changes sufficient for desensitization without heteromer activation. Bioluminescence resonance energy transfer and co-immunoprecipitation studies indicated an agonist-induced physical association between the D1-D2 receptor heteromeric complex and GRK2. Increased expression of GRK2 led to a decrease in the calcium signal with or without prior exposure to either SKF 83959 or SKF 83822. GRK2 knockdown by siRNA led to an increase in the signal after pretreatment with either agonist. Expression of the catalytically inactive and RGS (regulator of G protein signaling)-mutated GRK2 constructs each led to a partial recovery of the GRK2-attenuated calcium signal. These results indicated that desensitization of the dopamine D1-D2 receptor heteromer-mediated signal can occur by agonist occupancy even without activation and is dually regulated by both the catalytic and RGS domains of GRK2.
Verma
Vaneeta
V
Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
Hasbi
Ahmed
A
O'Dowd
Brian F
BF
George
Susan R
SR
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology*; D002460:Cell Line; D018491:Dopamine Agonists / Q000494:pharmacology; D054769:G-Protein-Coupled Receptor Kinase 2 / Q000235:genetics / Q000378:metabolism*; D055785:Gene Knockdown Techniques; D006801:Humans; D051379:Mice; D009474:Neurons / Q000166:cytology / Q000378:metabolism*; D055503:Protein Multimerization / Q000187:drug effects / Q000502:physiology*; D017434:Protein Structure, Tertiary; D017447:Receptors, Dopamine D1 / Q000235:genetics / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000235:genetics / Q000378:metabolism*; D014793:Visual Cortex / Q000166:cytology / Q000378:metabolism*
C494644:3-allyl-6-chloro-7,8-dihydroxy-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; D001552:Benzazepines; D018491:Dopamine Agonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; C080703:SK&F 83959; C496567:GRK2 protein, human; C496568:GRK2 protein, mouse; D054769:G-Protein-Coupled Receptor Kinase 2; D002118:Calcium
Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):654-9
17194762
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3684-9
10725388
J Biol Chem. 2001 Dec 21;276(51):48040-7
11673456
Mol Pharmacol. 2000 Jul;58(1):120-8
10860933
Science. 2003 May 23;300(5623):1256-62
12764189
Mol Pharmacol. 2005 Oct;68(4):1039-48
15985612
J Biol Chem. 2004 Feb 27;279(9):7999-8010
14660631
J Biol Chem. 2006 Apr 21;281(16):10856-64
16492667
Nat Neurosci. 2000 Mar;3(3):226-30
10700253
J Biol Chem. 2005 Nov 4;280(44):37225-35
16115864
Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8606-11
10890919
Mol Pharmacol. 2007 Aug;72(2):450-62
17519357
J Biol Chem. 2003 Jan 31;278(5):3378-85
12433920
Mol Pharmacol. 2005 Sep;68(3):568-78
15923381
J Biol Chem. 2004 May 28;279(22):23214-22
15054093
Eur J Endocrinol. 2007 Apr;156 Suppl 1:S13-S21
17413183
Pharmacol Rev. 2001 Mar;53(1):1-24
11171937
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3399-404
16492766
J Biol Chem. 2004 Apr 16;279(16):16614-20
14764583
J Biol Chem. 2003 Mar 21;278(12):10562-71
12524448
J Biol Chem. 2004 Jan 2;279(1):686-91
14559905
Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21377-82
19948956
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10782-7
12949261
J Biol Chem. 2002 Mar 15;277(11):9415-21
11773080
Br J Pharmacol. 1996 May;118(1):167-73
8733591
J Biol Chem. 1998 Nov 13;273(46):30244-8
9804783
Annu Rev Pharmacol Toxicol. 1998;38:289-319
9597157
J Biol Chem. 2006 Jul 21;281(29):20577-88
16687412
J Neurochem. 2002 Aug;82(3):683-97
12153492
J Biol Chem. 2004 Aug 20;279(34):35671-8
15159403
J Biol Chem. 2005 Jun 10;280(23):22165-71
15817484
Prog Neurobiol. 2002 Feb;66(2):61-79
11900882
Neuroscience. 2000;98(4):749-57
10891618
J Neurosci. 2008 May 28;28(22):5671-85
18509028
J Biol Chem. 2009 Dec 4;284(49):34103-15
19815545
J Biol Chem. 2003 Jan 10;278(2):896-907
12417595
J Biol Chem. 2005 Jan 21;280(3):2197-204
15542600
Nat Struct Biol. 2001 Dec;8(12):1069-73
11702071
J Biol Chem. 2003 Feb 21;278(8):6050-8
12427730
Eur Neuropsychopharmacol. 1999 Jan;9(1-2):1-7
10082221
Nat Chem Biol. 2005 Jun;1(1):25-8
16407989
Neurochem Int. 2001 Aug;39(2):117-25
11408090
J Neurosci. 1995 Dec;15(12):8167-76
8613751